Novo Nordisk A/S News - September 2026
Novo Nordisk Licenses Hengrui’s Weekly Oral Obesity Drug in Up-to-$2.6B Deal
Novo Nordisk has signed an exclusive licensing agreement with Chinese drugmaker Hengrui Pharma for HRS-1596, an experimental once-weekly oral weight-loss drug...
Novo Nordisk signs €1.17B Nanexa deal, targeting monthly obesity injections
Novo Nordisk signed a global licensing agreement with Swedish firm Nanexa for its PharmaShell technology. The deal carries a total potential value of up to...
Novo Nordisk’s CagriSema Beats Eli Lilly in Weight Loss Trial
Novo Nordisk announced positive topline results for its next-generation experimental drug, CagriSema, during its Capital Markets Day. The late-stage REIMAGINE...
🔴 Novo Nordisk is trading 6% down; no confirmed September 21, 2026 announcement explains decline
Novo Nordisk is trading 6.23% down at DKK 264.00, with no confirmed September 21, 2026 company announcement directly explaining the decline. - Investors are...
Novo Nordisk wins China approval for Wegovy, first GLP-1 for liver disease
Novo Nordisk announced Thursday that China’s National Medical Products Administration approved Wegovy for a new medical use. The drug will treat metabolic...
Novo Nordisk Wegovy Cuts Obesity in 40% of Children, Trial Finds
Novo Nordisk reported positive results from its late-stage STEP Young trial for semaglutide in children aged 6 to under 12. Semaglutide serves as the active...
Novo Nordisk Launches Wegovy Pill in Germany, Marking First EU Entry
Novo Nordisk launched the oral version of its Wegovy weight-loss drug in Germany on September 1, 2026. This release marks the first entry of the GLP-1 pill...